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aggressively than appendicular skeleton OS, resulting in a better therapeutic
response to either surgery alone or multi-modality treatment. Here we report the
case of a 54-year old male diagnosed with high-grade chondroblastic OS of the man-
dible, who presented with painful swelling of the horizontal branch of the right man-
dible, accompanied by paresthesias and paroxystic pain episodes. The patient was
treated with aggressive surgery and adjuvant chemotherapy but, despite favorable
clinical prognostic factors, disease rapidly progressed to local and distant relapse,
causing the patient’s death 18 months after diagnosis.c 2005 Elsevier Ltd. All rights reserved.
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0Introduction
Compared to appendicular skeleton osteosarcoma,
osteosarcoma of the craniofacial bones (CFOS) has
better prognosis and rarely develops distant metas-
tases.1–3 Here we report a case of unusually
aggressive, high-grade, chondroblastic OS of the
mandible.741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reser
oi:10.1016/j.ooe.2005.07.006
* Corresponding author. Tel.: +39 06 5266 6919/6774; fax: +39
6 5266 5637.
E-mail address: milella@ifo.it (M. Milella).Case report
R.L., a 54-year old male, presented in March 2003
with a 3-month history of painful swelling of the
horizontal branch of the right mandible, accompa-
nied by paresthesias and paroxystic pain episodes
in the right mandibular trigeminal branch distribu-
tion territory. Orthopantomographic exam, inferior
occlusal X-rays, and dental CT scan demonstrated
limited interradicular osteolysis of 4.6, with reduc-
tion of bone density in the right horizontal branch
(Fig. 1A–C). Contrast-enhanced MRI revealedved.
Figure 1 (A) Orthopantomographic exam revealing an area of osteolysis in the right mandibular body, particularly in
the periapical region of 4.6, with shedding of the mesial root of 4.7. (B) Inferior occlusal X-rays showing apical and
periodontal reduction of bone mineral density of 4.5 and 4.4 involving the right emimandibula and the roots of 4.6 and
4.7. (C) Dental CT Scan demonstrated limited interradicular osteolysis of 4.6, with reduction of bone density in the
right horizontal branch. (D) and (E) Post contrast T1W STIR and T2 MRI demonstrating the extent of bone and soft tissue
involvement. The lesion appears hypointense in T1 and hyperintense in T2 and shows contrast-enhancement. (F)
Intraoral examination revealing a normal mucosa with congested areas. (G) Surgical examination showing a white-gray,
translucent mass, adhering loosely to the bone and firmly to the periostium. (H) High grade chondroblastic OS;
chondroblastic activity with atypical osteosarcoma cells arranged in palisades and sometimes in vortexes (EE 10X). (I)
At higher magnification (EE 20X) small atypical osteoblasts with one or more nuclei in the contest of dilated blood
vessels and polymorphic chondroblastic proliferation are observed.
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right half of the mandible from the angle to the
symphisis with partial involvement of the vertical
branch up to the sigmoid incisure and extension
to the surrounding soft tissues (Fig. 1D–E). Biopsy
(Fig. 1F–G) revealed small, atypical, sometimes
multi-nucleated osteoblasts in the context of di-
lated blood vessels and polymorphic chondroblastic
proliferation, allowing a diagnosis of high-grade
chondroblastic OS (Fig. 1H–I). Right emimandibu-
lectomy followed by reconstruction with fibular
osteocutaneous free flap was performed. Histolog-
ical examination confirmed the diagnosis of high-
grade OS of the mandible and demonstrated
complete excision of a 8 cm lesion, with wide
(>5 mm) margins. During adjuvant polychemother-
apy, the patient experienced local relapse and
underwent salvage surgery (total mandibulectomy)
followed by external beam radiation therapy, but
died of further local relapse and pulmonary meta-
static disease 18 months after diagnosis, despite
palliative chemotherapy.Discussion
CFOS accounts for 6–10% of all OS, with mandibular
location in approximately 40%of patients.1–3 Several
differences in disease characteristics distinguish
CFOS and OS at other primary sites: CFOS most com-
monly affects patients in their 30 s; distant metasta-
ses are rarely reported (10–20%of patients); survival
after surgery alone has historically been better for
CFOS than for OS arising at other locations, with
reported 5-year survival rates of 23–37% and 10–
20% for CFOS and other OS, respectively.1–6
Complete surgical excision with adequate mar-
gins (>5 mm) is the mainstay of treatment for
CFOS.1–6 Conversely, the role of pre-and/or post-
operative chemotherapy is more controversial.
Although two recent meta-analysis have yielded
conflicting results4,5 and despite the lack in survivaldifferences between patients treated with surgery
alone and surgery + chemotherapy in the largest
series reported to date,1 the prognosis of CFOS
has steadily improved over the past 20 years, at
least in part due the introduction of multi-agent
chemotherapy.
Factors associated with a poor prognosis are age
older than 60 years, non-mandibular location,
tumor size >6 cm, osteoblastic histology, advanced
stage, non-surgical initial therapy, and positive
resection margins.1 In the case of mandibular OS
presented here, despite the presence of tumor size
>6 cm as the only adverse prognostic factor, dis-
ease displayed an extremely aggressive clinical
course, with local relapse occurring during adju-
vant chemotherapy and development of distant
metastases early in the course of disease. Such an
unusual behavior highlights the inadequacy of clin-
ical parameters to correctly predict prognosis in
individual patients and the need for a better under-
standing of the biology of CFOS, as well as of other
malignancies.References
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